Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRSHNASDAQ:CFRXNASDAQ:FRTXNASDAQ:VIRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRSHBruush Oral Care$0.00$0.00$0.04▼$8.50N/A2.7614.13 million shs25,691 shsCFRXContraFect$0.05$0.05$0.04▼$13.02$535K0.291.39 million shs910,216 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsVIRIVirios Therapeutics$4.56$5.30$0.13▼$1.04$87.82M1.581.05 million shs104,583 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRSHBruush Oral Care0.00%-12.50%-12.50%-63.16%-98.84%CFRXContraFect0.00%0.00%0.00%0.00%0.00%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%+0.54%+2.60%VIRIVirios Therapeutics0.00%-9.16%+55.10%-48.00%+1,184.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBRSHBruush Oral CareN/AN/AN/AN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVIRIVirios Therapeutics0.1531 of 5 stars1.30.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRSHBruush Oral Care 0.00N/AN/AN/ACFRXContraFect 0.00N/AN/AN/AFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AVIRIVirios Therapeutics 2.50Moderate Buy$3.00-34.21% DownsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRSHBruush Oral Care$2.92M0.00N/AN/A($4.30) per share0.00CFRXContraFectN/AN/AN/AN/A($19.92) per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56VIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRSHBruush Oral CareN/AN/A0.00∞N/AN/AN/AN/AN/ACFRXContraFect-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRSHBruush Oral CareN/AN/AN/AN/AN/ACFRXContraFectN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRSHBruush Oral CareN/AN/AN/ACFRXContraFectN/A0.530.53FRTXFresh Tracks TherapeuticsN/AN/AN/AVIRIVirios TherapeuticsN/A7.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRSHBruush Oral Care31.85%CFRXContraFect7.85%FRTXFresh Tracks Therapeutics25.04%VIRIVirios Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipBRSHBruush Oral Care29.81%CFRXContraFect0.62%FRTXFresh Tracks Therapeutics0.23%VIRIVirios Therapeutics12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRSHBruush Oral Care11511,000359,000Not OptionableCFRXContraFect2310.70 million10.64 millionNot OptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableBRSH, CFRX, FRTX, and VIRI HeadlinesRecent News About These CompaniesVirios Therapeutics (NASDAQ:VIRI) Stock Price Down 1.5% - Time to Sell?May 12 at 4:17 AM | marketbeat.comVirios Therapeutics (NASDAQ:VIRI) Shares Up 14.5% - Here's What HappenedApril 21, 2025 | marketbeat.comDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comDogwood announces first patient dosed in Phase 2b trial on HalneuronJanuary 22, 2025 | markets.businessinsider.comPolluted communities hold their breath as companies struggle with California’s diesel truck banDecember 10, 2024 | apnews.comDogwood Therapeutics faces potential Nasdaq delistingNovember 24, 2024 | uk.investing.comDogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18, 2024 | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 31, 2024 | finanznachrichten.deDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | finance.yahoo.comMedia Sentiment Over TimeBRSH, CFRX, FRTX, and VIRI Company DescriptionsBruush Oral Care NASDAQ:BRSH$0.0007 0.00 (0.00%) As of 05/9/2025Bruush Oral Care Inc., an oral care company, manufactures and sells electric toothbrushes in the United States and Canada. It offers Brüush starter kit, including electric toothbrush, three brush heads, a magnetic charging stand and USB power adapter, and a travel case. It also provides brush head refills. The company sells its products through its website www.bruush.com. Bruush Oral Care Inc. was incorporated in 2017 and is based in Vancouver, Canada.ContraFect NASDAQ:CFRXContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Virios Therapeutics NASDAQ:VIRI$4.56 0.00 (0.00%) As of 05/9/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
